{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T21:05:16Z","timestamp":1779311116735,"version":"3.51.4"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T00:00:00Z","timestamp":1592006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T00:00:00Z","timestamp":1592006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s10096-020-03941-5","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T10:03:43Z","timestamp":1594202623000},"page":"2199-2203","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A comparison of daptomycin alone and in combination with ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bacteremia complicated by septic pulmonary emboli"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1094-043X","authenticated-orcid":false,"given":"Taylor","family":"Morrisette","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdalhamid M.","family":"Lagnf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Alosaimy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Rybak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,13]]},"reference":[{"key":"3941_CR1","unstructured":"Centers for Disease Control and Prevention (CDC). Antibiotic resistance threats in the United States, 2019. Available from: https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf. Accessed November 14, 2019."},{"key":"3941_CR2","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1093\/cid\/cit178","volume":"56","author":"SJ van Hal","year":"2013","unstructured":"van Hal SJ, Fowler VG Jr (2013) Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections? Clin Infect Dis 56:1779\u20131788","journal-title":"Clin Infect Dis"},{"key":"3941_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.2174\/1874306401408010028","volume":"8","author":"U Goswami","year":"2014","unstructured":"Goswami U, Brenes JA, Punjabi GV, LeClaire MM, Williams DN (2014) Associations and outcomes of septic pulmonary emboli. Open Respir Med J 8:28\u201333","journal-title":"Open Respir Med J"},{"key":"3941_CR4","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1086\/430352","volume":"191","author":"JA Silverman","year":"2005","unstructured":"Silverman JA, Mortin LE, VanPraagh ADG, Li T, Alder J (2005) Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 191:2149\u20132152","journal-title":"J Infect Dis"},{"key":"3941_CR5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.diagmicrobio.2018.09.004","volume":"93","author":"RL Crass","year":"2019","unstructured":"Crass RL, Powell KL, Huang AM (2019) Daptomycin for the treatment of Staphylococcus aureus infections complicated by septic pulmonary emboli. Diagn Microbiol Infect Dis 93:131\u2013135","journal-title":"Diagn Microbiol Infect Dis"},{"key":"3941_CR6","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1001\/archinte.1983.00350100036011","volume":"143","author":"D Wong","year":"1983","unstructured":"Wong D, Chandraratna AN, Wishnow RM, Dusitnanond V, Nimalasuriya A (1983) Clinical implications of large vegetations in infectious endocarditis. Arch Intern Med 143:1874\u20131877","journal-title":"Arch Intern Med"},{"key":"3941_CR7","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1093\/jac\/dkn372","volume":"62","author":"SJ Rehm","year":"2008","unstructured":"Rehm SJ, Boucher H, Levine D et al (2008) Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. J Antimicrob Chemother 62:1413\u20131421","journal-title":"J Antimicrob Chemother"},{"key":"3941_CR8","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.eimc.2009.07.015","volume":"28","author":"Z Kanafani","year":"2010","unstructured":"Kanafani Z, Boucher H, Fowler V et al (2010) Daptomycin compared to standard therapy for the treatment of native valve endocarditis. Enferm Infecc Microbiol Clin 28:498\u2013503","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"3941_CR9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1128\/AAC.01586-12","volume":"57","author":"BJ Werth","year":"2013","unstructured":"Werth BJ, Sakoulas G, Rose WE, Pgliano J, Tewhey R, Rybak MJ (2013) Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic\/pharmacodynamics model. Antimicrob Agents Chemother 57:66\u201373","journal-title":"Antimicrob Agents Chemother"},{"key":"3941_CR10","doi-asserted-by":"publisher","unstructured":"Geriak M, Haddad F, Rizvi K et al (2019) Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 63. https:\/\/doi.org\/10.1128\/AAC.02483-18","DOI":"10.1128\/AAC.02483-18"},{"key":"3941_CR11","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa053783","volume":"355","author":"VG Fowler Jr","year":"2006","unstructured":"Fowler VG Jr, Boucher HW, Corey GR et al (2006) Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355:653\u2013665","journal-title":"N Engl J Med"},{"key":"3941_CR12","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1128\/AAC.02331-12","volume":"57","author":"Y Harada","year":"2013","unstructured":"Harada Y, Yanagihara K, Yamada K et al (2013) In vivo efficacy of daptomycin against methicillin-resistant Staphylococcus aureus in a mouse model of hematogenous pulmonary infection. Antimicrob Agents Chemother 57:2841\u20132844","journal-title":"Antimicrob Agents Chemother"},{"key":"3941_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/jac\/21.1.33","volume":"21","author":"PA Kephart","year":"1988","unstructured":"Kephart PA, Esposito AL (1988) Comparison of the investigational drug, LY146032, with vancomycin in experimental pneumonia due to methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 21:33\u201339","journal-title":"J Antimicrob Chemother"},{"key":"3941_CR14","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1159\/000238615","volume":"34","author":"A Verghese","year":"1988","unstructured":"Verghese A, Haire C, Franzus B, Smith K (1988) LY146032 in a hamster model of Staphylococcus aureus pneumonia\u2014effect on in vivo clearance and mortality and in vitro opsonophagocytic killing. Chemotherapy 34:497\u2013503","journal-title":"Chemotherapy"},{"key":"3941_CR15","doi-asserted-by":"publisher","first-page":"4471","DOI":"10.1128\/AAC.00210-10","volume":"54","author":"HS Heine","year":"2010","unstructured":"Heine HS, Basset J, Miller L, Purcell BK, Byrne WR (2010) Efficacy of daptomycin against Bacillus anthracis in a murine model of anthrax spore inhalation. Antimicrob Agents Chemother 54:4471\u20134473","journal-title":"Antimicrob Agents Chemother"},{"key":"3941_CR16","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1086\/533441","volume":"46","author":"PE Pertel","year":"2008","unstructured":"Pertel PE, Bernardo P, Fogarty C et al (2008) Effects of prior effective therapy on the efficacy on daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis 46:1142\u20131151","journal-title":"Clin Infect Dis"},{"key":"3941_CR17","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.2169\/internalmedicine.52.0023","volume":"52","author":"H Hagiya","year":"2013","unstructured":"Hagiya H, Hagioka S, Otsuka F (2013) Ineffectiveness of daptomycin in the treatment of septic pulmonary emboli and persistent bacteremia caused by methicillin-resistant Staphylococcus aureus. Intern Med 52:2577\u20132582","journal-title":"Intern Med"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-020-03941-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-020-03941-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-020-03941-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T23:42:53Z","timestamp":1623541373000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-020-03941-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,13]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["3941"],"URL":"https:\/\/doi.org\/10.1007\/s10096-020-03941-5","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,13]]},"assertion":[{"value":"18 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MJR has received grant support, consulted, or spoken on behalf of Accelerate, Allergan, Bayer, Melinta, Merck, Motif, Nabriva, Paratek, Qupex, Shionogi, and Tetraphase, and he is partially supported by NIH R01 Al12400. TM, AML, and SA have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}